Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Afisi Ismaila (Research Triangle Park , United States of America), Eline Huisman, Katya Sion, Yogesh Punekar, Andreas Karabis, Ian Naya, Afisi Ismaila. Comparative efficacy of umeclidinium/vilanterol versus LABA/LAMA therapies in COPD: A network meta-analysis. Eur Respir J 2016; 48: Suppl. 60, 981

Member's Comments

No comment yet.

Related content which might interest you: Overall and cardiovascular safety of aclidinium/formoterol fixed-dose combination versus salmeterol/fluticasone in patients with COPD Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015 LABA/LAMA combination in COPD: a meta-analysis on the duration of treatment Source: Eur Respir Rev 2017; 26: 160043 Year: 2017 Efficacy of aclidinium/formoterol fixed-dose combination versus salmeterol/fluticasone in COPD Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015 Once-daily QVA149 demonstrates superior outcomes in COPD patients previously treated with fixed-dose long-acting beta2-agonist/inhaled corticosteroid (LABA/ICS): The ILLUMINATE study Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 Comparison of cardiovascular safety in a pooled analysis of COPD trials comparing tiotropium with salmeterol Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013 Effectiveness of combination therapy with tiotropium in COPD. A secondary analysis of the UPLIFT trial Source: Annual Congress 2009 - Functional insights into COPD Year: 2009 Efficacy and safety of QVA149 compared with salmeterol/fluticasone combination (SFC) in Chinese patients with moderate-to-severe COPD: A subgroup analysis from the LANTERN study Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015 Triple therapy of umeclidinium and inhaled corticosteroid/long-acting β2-agonist (ICS/LABA) vs placebo + ICS/LABA in GOLD D patients Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 Efficacy and safety of umeclidinium/vilanterol compared with umeclidinium or tiotropium in COPD Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 Safety of tiotropium and olodaterol fixed-dose combination for COPD in patients on β-blockers Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 A novel study design for the comparison between once-daily QVA149 and twice-daily salmeterol/fluticasone on the reduction of COPD exacerbations: The FLAME study Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013 Efficacy and safety profile of xanthines in COPD: a network meta-analysis Source: International Congress 2018 – Innovative therapies in asthma and COPD Year: 2018 Efficacy and safety profile of xanthines in COPD: a network meta-analysis Source: Eur Respir Rev, 27 (148) 180010; 10.1183/16000617.0010-2018 Year: 2018 Comparison of LAMA/LABA vs ICS/LABA in high risk COPD patients: Pre-specified analysis on lung function and health status from the IMPACT trial Source: International Congress 2018 – COPD management Year: 2018 Once-daily QVA149 provides the same efficacy as the free combination of its monocomponents indacaterol and glycopyrronium: The BEACON study Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 Assessment of efficacy and tolerability of roflumilast add-on to LABA/LAMA/ICS in the treatment of COPD in Indian patients Source: International Congress 2016 – Novel avenues in the treatment of COPD I Year: 2016 Cost-effectiveness of fixed-dose combinations therapies for COPD in Spain Source: International Congress 2017 – Does economisation of medicine transfer into benefits for patients? Year: 2017 Comparative assessment of umeclidinium/vilanterol (UMEC/VI) combination therapy among symptomatic COPD patients Source: International Congress 2014 – Asthma and COPD management Year: 2014 Effect of triple therapy with extra-fine BDP/FF/GB pMDI vs non-triple maintenance therapies on severe COPD exacerbations. A pooled analysis of the TRILOGY, TRINITY and TRIBUTE studies. Source: Virtual Congress 2020 – Clinical studies of COPD: combination inhalers and much more Year: 2020 Clinical synergism of LABA/LAMA combinations in COPD patients Source: International Congress 2017 – Bronchodilators and bronchoprotectors Year: 2017